Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer
- PMID: 25175925
- DOI: 10.3892/ijo.2014.2627
Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer
Abstract
Ovarian cancer is the fifth leading cause of cancer death and the most deadly gynecological malignancy in women. Epigenetic modifications play an important role in regulating gene transcription. Specifically, aberrant promoter hypermethylation has been implicated as a hallmark of cancer. In order to identify genes that are differentially methylated in ovarian cancer, we performed meDIP-chip in various ovarian cancer cell lines using Agilent 244K CpG island microarray. One of the targets, ARNTL which is a core component of the circadian clock is methylated in a sub-set of ovarian cancer cell lines. Combined bisulfite restriction analysis (COBRA) confirmed the results of the microarray. Additional analysis using ChIP-PCR revealed that promoter of ARNTL is enriched with the repressive histone mark H3K27me3 in CP70 and MCP2 ovarian cancer cells. Treatment with the EZH2 inhibitor (GSK126) significantly restored ARNTL expression in these cells (CP70 and MCP2). Further functional analysis demonstrated that overexpression of ARNTL inhibited cell growth and enhanced chemosensitivity of cisplatin in ovarian cancer cells. Finally, overexpression of ARNTL restored the rhythmic activity of c-MYC in ovarian cancer cells. These results suggested that ARNTL may be a tumor suppressor and is epigenetically silenced in ovarian cancer.
Similar articles
-
Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.Cancer Res. 2003 Jul 15;63(14):4174-80. Cancer Res. 2003. PMID: 12874023
-
Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies.Cancer Res. 2009 Nov 1;69(21):8447-54. doi: 10.1158/0008-5472.CAN-09-0551. Epub 2009 Oct 27. Cancer Res. 2009. PMID: 19861541
-
Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.Cytotherapy. 2013 Sep;15(9):1164-73. doi: 10.1016/j.jcyt.2013.05.001. Epub 2013 Jun 22. Cytotherapy. 2013. PMID: 23800731
-
Epigenetics in ovarian cancer.Methods Mol Biol. 2012;863:253-69. doi: 10.1007/978-1-61779-612-8_15. Methods Mol Biol. 2012. PMID: 22359298 Review.
-
Gene methylation in gastric cancer.Clin Chim Acta. 2013 Sep 23;424:53-65. doi: 10.1016/j.cca.2013.05.002. Epub 2013 May 10. Clin Chim Acta. 2013. PMID: 23669186 Review.
Cited by
-
A seven-immune-genes risk model predicts the survival and suitable treatments for patients with skin cutaneous melanoma.Heliyon. 2023 Sep 19;9(9):e20234. doi: 10.1016/j.heliyon.2023.e20234. eCollection 2023 Sep. Heliyon. 2023. PMID: 37809963 Free PMC article.
-
Integrative analysis of circadian clock with prognostic and immunological biomarker identification in ovarian cancer.Front Mol Biosci. 2023 Jun 20;10:1208132. doi: 10.3389/fmolb.2023.1208132. eCollection 2023. Front Mol Biosci. 2023. PMID: 37409345 Free PMC article.
-
Down-regulation of BMAL1 by MiR-494-3p Promotes Hepatocellular Carcinoma Growth and Metastasis by Increasing GPAM-mediated Lipid Biosynthesis.Int J Biol Sci. 2022 Oct 18;18(16):6129-6144. doi: 10.7150/ijbs.74951. eCollection 2022. Int J Biol Sci. 2022. PMID: 36439870 Free PMC article.
-
Cold Atmospheric Plasma Targeting Hematological Malignancies: Potentials and Problems of Clinical Translation.Antioxidants (Basel). 2022 Aug 17;11(8):1592. doi: 10.3390/antiox11081592. Antioxidants (Basel). 2022. PMID: 36009311 Free PMC article. Review.
-
5-Acetamido-1-(methoxybenzyl) isatin inhibits tumor cell proliferation, migration, and angiogenesis.RSC Adv. 2019 Nov 11;9(63):36690-36698. doi: 10.1039/c9ra07002h. eCollection 2019 Nov 11. RSC Adv. 2019. PMID: 35539063 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical